Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 2Recurrence 1Prostatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Breast Cancer 1

Interventions

Fulvestrant 13Letrozole 6Anastrozole 5palbociclib 4exemestane 3Injections 3Docetaxel 3Paclitaxel 2Goserelin 2Dasatinib 2Capecitabine 2Alpelisib 2AZD9833 2vandetanib 1ribociclib 1irinotecan sucrosofate 1entinostat 1elacestrant 1cediranib 1abemaciclib 1XMT-1522 1Vinorelbine 1Sirolimus 1Ritonavir 1Lead 1Itraconazole 1Immunotherapy, Adoptive 1Everolimus 1Decitabine 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer × CYH33 × Clear all
NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
228 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡